C39H45N9O5
Neat
719.8
NX-2127; NX2127; NX 2127; RefChem:1093337; BTK Degrader NX-2127; CTM NX-2127; Chimeric Targeting Molecule NX-2127; Bruton's Tyrosine Kinase Degrader NX-2127; 2416131-46-7; 2-Pyrazinecarboxamide, 3-[[4-[1-[[(3S)-1-[2-(2, 6-dioxo-3-piperidinyl)-2, 3-dihydro-1, 3-dioxo-1H-isoindol-5-yl]-3-pyrrolidinyl]methyl]-4-piperidinyl]phenyl]amino]-5-(1-piperidinyl)-; Zelebrudomide, (S)-; 3-[[4-[1-[[(3S)-1-[2-(2, 6-Dioxo-3-piperidinyl)-2, 3-dihydro-1, 3-dioxo-1H-isoindol-5-yl]-3-pyrrolidinyl]methyl]-4-piperidinyl]phenyl]amino]-5-(1-piperidinyl)-2-pyrazinecarboxamide; 3-[4-[1-[[(3S)-1-[2-(2, 6-dioxopiperidin-3-yl)-1 and 3-dioxoisoindol-5-yl]pyrrolidin-3-yl]methyl]piperidin-4-yl]anilino]-5-piperidin-1-ylpyrazine-2-carboxamide; LSC67HA8DE; orb1744147; CHEMBL5563501; SCHEMBL21947733; GTPL13490; EX-A7600; AT41576
3-[4-[1-[[(3S)-1-[2-(2, 6-dioxopiperidin-3-yl)-1 and 3-dioxoisoindol-5-yl]pyrrolidin-3-yl]methyl]piperidin-4-yl]anilino]-5-piperidin-1-ylpyrazine-2-carboxamide
InChI=1S/C39H45N9O5/c40-35(50)34-36(43-32(21-41-34)46-15-2-1-3-16-46)42-27-6-4-25(5-7-27)26-13-17-45(18-14-26)22-24-12-19-47(23-24)28-8-9-29-30(20-28)39(53)48(38(29)52)31-10-11-33(49)44-37(31)51/h4-9,20-21,24,26,31H,1-3,10-19,22-23H2,(H2,40,50)(H,42,43)(H,44,49,51)/t24-,31?/m0/s1